Early detection of respiratoty disorders in non-affective psychotic patients

Clinical Research Results Abstract IntroductionTobacco and cannabis use is highly prevalent among patients with psychotic disorder. Smoking is the main risk factor for chronic respiratory diseases and one of the main causes of increased mortality in this subpopulation. The state of respiratory health and its possible association with outcome measures such as quality of life is not widely described in psychosis.The objective of this study is to evaluate the presence of chronic respiratory pathology in a sample of patients with psychotic disorder,10 years after the debut of the disease.MethodsThe respiratory function of a sample of patients with a first episode of psychosis (n=128) and of a sample of control (n=79) was evaluated. The functional tests consisted of spirometry enforced with bronchodilatation and diffusion of CO. Both groups answered dyspnea and quality of life tests (WHOQOL-BREF)Results207 individuals (53.1% men) were evaluated. 56% had active tobacco consumption (of which 7.4% also used cannabis). 62 were "ex-smokers" (more than 6 months without tobacco and / or cannabis use). We found no significant differences in the mean mMRC score between groups (0.47 vs 0.37, p=0.367). However, when exploring differences in the dyspnea threshold (mMRC ≥2) we observed a significant difference between groups (8 vs 0%; X2=5.282, p=0.024). Similarly, patients presented higher scores in the Dyspnea-12 scale than controls (4.5 vs 2.0, F=12.525, p=0.001).The baseline spirometry showed mean values ​​of FVC of 4.25 L (105% reference value) vs 4.72 L (p=0.002) and FEV1 of 3.29 L (96.8% reference value) vs 3.75 (p<0.001). The CO diffusion test showed an average lung diffusion capacity of 71.42% vs 84.93% (p<0.001). Patients referred a significant (all p<0.001) poorer quality of life than controls in the four WHOQOL-BREF domains.DiscussionThe results allow us to emphasize the importance of monitoring the state of respiratory health in the population of patients with psychosis, in primary care and at early stages, given the risk factors they present. Research Idea Abstract Service Development & Evaluation Abstract Declaration of Interest Clinical Trials.gov Identifier:NCT03476473Funding source:Valdecilla Biosanitary Investigation Institute (IDIVAL) grantPRIM-VAL17/06 (6000 euros) References and Clinical Trial Registry Information Clinical Trials.gov Identifier:NCT03476473